FORWARD LOOKING STATEMENT

This presentation contains forward-looking statements & estimates made by the management of the Company with respect to the anticipated future performance of MDxHealth & the market in which it operates. Such statements & estimates are based on various assumptions & assessments of known & unknown risks, uncertainties & other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict & may depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or achievements of MDxHealth, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements & estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements & estimates. MDxHealth disclaims any obligation to update any such forward-looking statement or estimates to reflect any change in the Company's expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement or estimate is based, except to the extent required by Belgian law.

ANALYST COVERAGE

Any opinions, estimates or forecasts made by analysts are theirs alone and do not represent opinions, forecasts or predictions of MDxHealth or its management. Requests for copies of analyst reports should be directed at the respective analyst & institution.
OUR MISSION

Improve patient outcomes by delivering molecular diagnostic solutions for urologic cancers

PROSTATE CANCER

589,679 new cases

BLADDER CANCER

242,273 new cases

KIDNEY CANCER

176,500 new cases

THE LEADER IN MOLECULAR DIAGNOSTICS FOR URO-ONCOLOGY

GLOBOCAN 2012 (IARC) Population forecasts were extracted from the United Nations, World Population prospects, the 2012 revision. Numbers are computed using age-specific rates and corresponding populations for 10 age-groups.

THE LEADER IN MOLECULAR DIAGNOSTICS FOR URO-ONCOLOGY
MDXHEALTH LEADS MOLECULAR DIAGNOSTICS FOR UROLOGY

- >100,000 patients tested globally
- 240 employees dedicated to MDxHealth global foot-print
- >70 scientific publications supporting the products
- $319 Million market cap Euronext; MDXH.BR
- > $100 Million in revenue since launch of first product
- >50% lives covered for lead product

15 YEARS since the company was founded in 2003
2017 PRODUCT HIGHLIGHTS

**Select MDx**
- 11,700 Patients tested
- EU Volume of 300%
- 4 New payor contracts
- 9 European distribution agreements
- 3 2 Clinical publications and 1 abstract

**Confirm MDx**
- 21,400 Patients tested
- 18 New payor contracts
- 2 Integrated Health Systems contracts
- 4 New payor contracts
- 6 3 Clinical publications and 3 abstracts

**Assure MDx**
- 1 Clinical publication
GROWTH STRATEGY

FOUR KEY PILLARS

1. Drive tests adoption with urologists and payors.
2. Increase the clinical utility of SelectMDx.
3. Expand usability tests through IVD Platform.
4. Precision diagnostics through pharma partnering.

The growing incidence of cancer globally
Demand for fast, actionable, cost-effective diagnosis and patient monitoring
COMMERCIAL STRATEGY OVERVIEW

**US Operations**
- CLIA service lab (215 FTE’s)
- Laboratory developed test (LDT)
- Large national sales force 42 reps
- Reimbursement Medicare & commercial

**EU Operations**
- ISO service lab (25 FTE’s)
- CE-marked in-vitro diagnostic (IVD) kits
- Direct sales 5 reps
- Distributors
PRODUCT PIPELINE & MARKET OPPORTUNITY

<table>
<thead>
<tr>
<th>Product Pipeline</th>
<th>R&amp;D</th>
<th>Validation</th>
<th>Clinical Utility</th>
<th>Launch</th>
<th>Market $M</th>
</tr>
</thead>
<tbody>
<tr>
<td>Select MDx for Prostate Cancer</td>
<td>![Arrows]</td>
<td>![Arrows]</td>
<td>![Arrows]</td>
<td>![Arrows]</td>
<td>$555</td>
</tr>
<tr>
<td>Confirm MDx for Prostate Cancer</td>
<td>![Arrows]</td>
<td>![Arrows]</td>
<td>![Arrows]</td>
<td>![Arrows]</td>
<td>$788</td>
</tr>
<tr>
<td>Assure MDx for Bladder Cancer</td>
<td>![Arrows]</td>
<td>![Arrows]</td>
<td>![Arrows]</td>
<td>![Arrows]</td>
<td>$1,874</td>
</tr>
<tr>
<td>Inform MDx for Prostate Cancer</td>
<td>![Arrows]</td>
<td>![Arrows]</td>
<td>![Arrows]</td>
<td>![Arrows]</td>
<td>$431</td>
</tr>
<tr>
<td>Monitor MDx for Prostate Cancer</td>
<td>![Arrows]</td>
<td>![Arrows]</td>
<td>![Arrows]</td>
<td>![Arrows]</td>
<td>$700</td>
</tr>
<tr>
<td>Kidney Cancer Assay</td>
<td>![Arrows]</td>
<td>![Arrows]</td>
<td>![Arrows]</td>
<td>![Arrows]</td>
<td>Not Disclosed</td>
</tr>
</tbody>
</table>
2017 TEST VOLUME AND REVENUE AT FULL REIMBURSEMENT

- **Confirm MDx** for Prostate Cancer:
  - 21,400 tests
  -Booked revenue: $26.4M
  -Revenue at full reimbursement: $43M

- **Select MDx** for Prostate Cancer:
  - 11,400 tests
  -Booked revenue: $1.8M
  -Revenue at full reimbursement: $3.4M

- **Assure MDx** for Bladder Cancer:
  - 1,500 patient clinical validation study
  -Booked revenue: $0.0M
  -Revenue at full reimbursement: $0.7M

- **Inform MDx** for Prostate Cancer:
  - Test under development
  -Booked revenue: $0.0M
  -Revenue at full reimbursement: $0.0M

**TOTAL PRODUCT REVENUE**
-Booked revenue: $28.2M
-Revenue at full reimbursement: $47.1M
PROSTATE CANCER CHALLENGES

Who needs initial biopsy? ~2.0M abnormal PSA test results³
Who needs repeat biopsy? ~500,000 prostate biopsy procedures⁴
Who needs treatment? 186,780 diagnosed with prostate cancer⁵

19M PSA Screenings¹²

~2.0M abnormal PSA test results³

~500,000 prostate biopsy procedures⁴

186,780 diagnosed with prostate cancer⁵

27,540 Deaths⁶


SelectMDx for Prostate Cancer

ConfirmMDx for Prostate Cancer

InformMDx for Prostate Cancer

MDxHealth
1. GLOBOCAN 2012 (IARC) Population forecasts were extracted from the United Nations, World Population prospects, the 2012 revision. Numbers are computed using age-specific rates and corresponding populations for 10 age groups.

Improving patient selection for prostate biopsy:
- 25% false-negative results
- ~3% hospitalized within 30 days of biopsy
- 18% complications from biopsy (e.g., bleeding, infections, etc.)

Prostate biopsy remains the gold standard for cancer detection.

1. GLOBOCAN 2012 (IARC) Population forecasts were extracted from the United Nations, World Population prospects, the 2012 revision. Numbers are computed using age-specific rates and corresponding populations for 10 age groups.

**VALUABLE LIQUID BIOPSY TEST FOR PATIENTS & PHYSICIANS**

- **Non-Invasive urine test**
- **Identifies patient for MRI or biopsy**
- **Avoiding 53% of unnecessary biopsies**

- **98%** NPV for high grade prostate cancer
- **2M** men with elevated PSA only 25% at risk for high grade disease

Available as LDT and IVD Product
Liquid Biopsy to Identify Patients for Prostate Biopsy

Elevated PSA / DRE → Urine Test → SelectMDx
for Prostate Cancer → MRI / BIOPSY → Follow-up

ROUTINE PSA

Urine test for the prediction of histopathological outcome of prostate biopsy
1. GLOBOCAN 2012 (IARC) Population forecasts were extracted from the United Nations, World Population prospects, the 2012 revision. Numbers are computed using age-specific rates and corresponding populations for 10 age groups.

**VALUABLE TISSUE BIOPSY TEST FOR PHYSICIANS & PAYORS**

- Tissue test in NCCN guidelines
- Medicare coverage
- Identifies men at risk for high grade disease
- Avoiding 53% of unnecessary repeat biopsies

- **96%** NPV for high grade prostate cancer
- **500K** initial biopsy, 25% false negative, 18% complications

*MDxHealth Lead Product*
TISSUE BIOPSY TO FORGO A REPEAT PROSTATE BIOPSY

- MRI / BIOPSY
- ROUTINE PSA
- Follow-up

Pathology
initial negative biopsy

DNA Tissue Test

Confirm MDx for Prostate Cancer
1. GLOBOCAN 2012 (IARC) Population forecasts were extracted from the United Nations, World Population prospects, the 2012 revision. Numbers are computed using age-specific rates and corresponding populations for 10 age groups.

PRODUCT SUCCESS SINCE LAUNCH

Select MDx®
for Prostate Cancer

>20,000 tests completed since launch May 2016

List Price: $500

Confirm MDx®
for Prostate Cancer

>80,000 tests completed since launch May 2016

List Price: $3,300
TOTAL ADDRESSABLE US MARKET

Confirm MDx® for Prostate Cancer

~7% Market Penetration

~320,000
Potential US ConfirmMDx Market

~$555M
Total Addressable Market*

*Based on selected studies and reports.
REIMBURSEMENT TIMELINES

2 – 4 Years

<table>
<thead>
<tr>
<th>Analytical Validation</th>
<th>Clinical Validation</th>
<th>Clinical Utility</th>
<th>Budget Impact Study</th>
<th>Clinical Guidelines</th>
<th>Payor Contracts</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Real World Clinical Utility</td>
<td>Select MDx</td>
<td>Comparative Effectiveness</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Investigational Use</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Test Commercially Available</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Payor Involvement (PPO)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

High

Clinical Adoption

Low

Early

Test Maturity (Level of Evidence)

Established
INCREASING COVERAGE

Covered Lives (Millions)

2013 2014 2015 2016 2017

0 40 80 120 160
Who should be referred?

Who gets cystoscopy?

Who has bladder cancer?

Who will recur?

How to treat?

10M HAEMATURIA PATIENTS

1.8M referrals to urology

>600,000 Cystoscopy Procedures

300,000 Active Monitoring

80,000 CASES

GLOBOCAN 2012 (IARC) Population forecasts were extracted from the United Nations, World Population prospects, the 2012 revision. Numbers are computed using age-specific rates and corresponding populations for 10 age groups.

**VALUABLE TISSUE BIOPSY TEST FOR PATIENTS & PHYSICIANS**

- **99%** NPV for bladder cancer
- **10M** Hematuria patients
  - Non-Invasive urine test
  - Recommends cystoscopy or CT scan
  - Avoiding unnecessary cystoscopies

Available as LDT and IVD Product
LIQUID BIOPSY TO IDENTIFY PATIENTS WITH BLADDER CANCER

CT Scan / Cystoscopy

Follow-up

Routine Monitoring

AssureMDx®
for Bladder Cancer

Patient
blood in urine

Urine Test
Runs on any open
PCR/Sequence instrument
Q1 2018 FINANCIAL HIGHLIGHTS

>9,300 Patients Tested
$9.7M Total Revenue
$6.7M Operating Loss
-$6.2M EBITDA

Growth Over Q1 2017: +55%
+50%
+$0.8M
+$0.8M

CASH and CASH EQUIVALENTS OF $51.3M
Q1 2018 HIGHLIGHTS

OPERATIONAL EXECUTION

- 50% Q1 volume increase for ConfirmMDx
- >167% SelectMDx volume increase in Europe
- 6 New payors contracts
- SelectMDx in EAU Guidelines

OTHER BUSINESS

- Sign global license with LabCorp for MGMT
- Published new Liquid Biopsy test for CRPC
- SelectMDx in Dutch Reimbursement system
Q1 2018 VOLUME GROWTH

>9,300 total patients tested (up 55%)

>167% SelectMDx volume increase since global launch

50% ComfirmMDx growth over Q1 2017
### THE MARKET CONTINUES TO RESPOND POSITIVELY

| Stock Exchanges | MDXH: Euronext BR  
<table>
<thead>
<tr>
<th></th>
<th>MDXDHF: OTC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Shares Outstanding</td>
<td>59,939,289</td>
</tr>
<tr>
<td>Market Cap</td>
<td>$3.56 - $6.75</td>
</tr>
</tbody>
</table>
| Analyst Coverage | U.S. Taglich Brothers  
|                 | Europe Berenberg Kempen KBC Degroof Petercam Goetzpartners |

**YTD Share Facts**
- 51.9% Retail
- 12.8% BioVest
- 12% Valiance
- 14.3% Other Institutionals
- 5.7% Capfi Delen
- 3.3% BNP Parisbas

**Shareholders**
COMPELLING INVESTMENT THESIS

**VISION**
To be a leading molecular diagnostics for urologic oncology focusing on innovation

**FUTURE**
Cancer incidence accelerating with aging population
Oncology is the fastest growing area in diagnostics

**GROWTH**
Established and fast growing specialty molecular uro-diagnostic business
Three commercial products on the market and tested >100,000 patients
Roadmap to profitability through product sales ramp

**PIPELINE**
Internal and external sourcing of new innovative assets to build pipeline
Ongoing business development efforts towards pharma companies
Strong focus on IVD market
UPCOMING NEWSFLOW

**Q2**
- **AUGUST 30, H1 RESULTS**
  - SelectMDx 4M validation study
  - Product distribution agreements for Select & ConfirmMDx
  - Licensing agreement InformMDx technology

**Q3**
- **OCTOBER 23, Q3 RESULTS**
  - Clinical utility & budget impact studies
  - Contracting with “sample-to-result” IVD platform partner for SelectMDx
  - Product distribution agreements for Select & ConfirmMDx

**Q4**
- **FEBRUARY 2019, Q4 RESULTS**
  - Filling for Medicare coverage of SelectMDx
  - Publication of data to expand SelectMDx utility
  - Distribution agreements ConfirmMDx and SelectMDx
2017 OVERVIEW

FINANCIAL PERFORMANCE

- 35% increase in total revenue
- $28.2M in Product & Service Revenue
- $40.5 in total revenue

OPERATIONAL EXECUTION

- >33,100 patients tested
- 14% Q4 volume increase for ConfirmMDx
- >300% SelectMDx volume increase in Europe
- 2 integrated health system contracts
FY 2017 FINANCIAL HIGHLIGHTS

~33K Patients Tested
$40.5M Total Revenue
$12.3M Operating Loss
-$10.4M EBITDA

Growth Since FY 2016:
+39%
+35%
-$0.5M
+$0.7M

CASH COLLECTION INCREASE +17%
CONTINUED REVENUE GROWTH

2015

$15.8M

$1.9M

2016

$24.9M

$5M

2017

$28.2M

$12.3M

$10M $20M $30M $40M

Products & Services Other

17% increase in cash collections from products & services to $23.1M

91% of product & service revenue represented by ConfirmMDx

$16.8M cash at December 31, 2017

35% increase in total revenue
CONTINUED STRONG VOLUME GROWTH

2015

2016

2017

10,000 20,000 30,000

ConfirmMDx SelectMDx (US) SelectMDx (EU)

>33,000 total patients tested (up 39%)

>300% SelectMDx volume increase since global launch

14% stronger Q4 performance reflects sales team growth
RESEARCH COLLABORATIONS
SUPPORT OUR PIPELINE

- Develop and validate blood based test for CRPC
- Development and validation of bladder cancer products
- Discovery and development of kidney cancer assays
OUR INTELLECTUAL PROPERTY

38 PATENT FAMILIES

23 ISSUED PATENTS
15 PENDING PATENTS

25 ISSUED PATENTS
20 PENDING PATENTS